RhumbLine Advisers
KZR

RhumbLine Advisers’s Kezar Life Sciences KZR Stock Holding History

RhumbLine Advisers’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,755
Closed -$16.5K – 4270
2024
Q2 		$16.5K Sell
2,755
-8,189
-75% -$62.2K ﹤0.01% 3896
2024
Q1 		$98.7K Buy
10,944
+258
+2% +$2.35K ﹤0.01% 3451
2023
Q4 		$101K Hold
10,686
– – ﹤0.01% 3442
2023
Q3 		$127K Sell
10,686
-669
-6% -$11.9K ﹤0.01% 3378
2023
Q2 		$278K Buy
11,355
+3,154
+38% +$82.1K ﹤0.01% 3060
2023
Q1 		$257K Buy
8,201
+228
+3% +$13.2K ﹤0.01% 2661
2022
Q4 		$561K Buy
7,973
+87
+1% +$6.45K ﹤0.01% 2412
2022
Q3 		$679K Buy
7,886
+1,249
+19% +$121K ﹤0.01% 2351
2022
Q2 		$549K Buy
6,637
+1,985
+43% +$175K ﹤0.01% 2457
2022
Q1 		$773K Buy
4,652
+605
+15% +$86.8K ﹤0.01% 2233
2021
Q4 		$677K Buy
4,047
+54
+1% +$6.1K ﹤0.01% 2383
2021
Q3 		$345K Buy
3,993
+108
+3% +$7.15K ﹤0.01% 2707
2021
Q2 		$211K Sell
3,885
-214
-5% -$12.2K ﹤0.01% 2913
2021
Q1 		$244K Sell
4,099
-199
-5% -$11.6K ﹤0.01% 2774
2020
Q4 		$224K Buy
4,298
+723
+20% +$40.2K ﹤0.01% 2794
2020
Q3 		$173K Sell
3,575
-439
-11% -$21K ﹤0.01% 2730
2020
Q2 		$208K Buy
4,014
+859
+27% +$43.3K ﹤0.01% 2749
2020
Q1 		$138K Buy
3,155
+980
+45% +$39.9K ﹤0.01% 2703
2019
Q4 		$87K Sell
2,175
-18
-0.8% -$554 ﹤0.01% 2884
2019
Q3 		$72K Buy
2,193
+186
+9% +$8.98K ﹤0.01% 2910
2019
Q2 		$155K Buy
2,007
+626
+45% +$97.3K ﹤0.01% 2855
2019
Q1 		$245K Buy
+1,381
New +$272K ﹤0.01% 2654

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RhumbLine Advisers's KZR Position: Q3 2024 in Review

RhumbLine Advisers sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 2,755 shares — an estimated $16.5K sold.

RhumbLine Advisers first reported a position in KZR in Q1 2019 and held it in 22 quarters. The position peaked at $773K in Q1 2022. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • RhumbLine Advisers reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 2,755 Kezar Life Sciences shares in Q3 2024, an estimated $16.5K.
  • RhumbLine Advisers first reported a position in Kezar Life Sciences in Q1 2019 and held it in 22 quarters.
  • RhumbLine Advisers's Kezar Life Sciences position peaked at $773K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.